Project Grant R01CA292385
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$371K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $554,653 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of RARECYTEFINDER, a label-free, genome-wide analysis method for unbiased identification and molecular profiling of rare disseminated tumor cells (DTCs) in liquid and tissue biopsies. The key products to be delivered under this 4-year project include: Advanced development and validation of RARECYTEFINDER for accurate detection and analysis of...
This $670,147 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at Vanderbilt University Medical Center (VUMC) to elucidate the molecular mechanisms governing the release and stability of cell-free DNA (cfDNA) in the bloodstream. The overarching goal is to increase the clinical sensitivity of liquid biopsies that detect circulating tumor DNA (ctDNA), which could enable more effective cancer...
This federal Project Grant award for $680,453, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to investigate the use of cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer (mCRPC). The 5-year study will pursue three specific aims: 1) determine if baseline cell-free tumor DNA (ctDNA) fragmentomics scores are prognostic...
This $201,172 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by Duke University to develop a non-invasive biomarker for profiling glioblastoma, an aggressive and deadly brain tumor. The project aims to use cell-free DNA methylation patterns to overcome limitations of current diagnostic approaches that rely on invasive surgical procedures. By identifying a prognostic biomarker for longitudinal monitoring, the research...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $181,640 to The University of Texas MD Anderson Cancer Center to conduct research on using liquid biopsy techniques to assess response to immunotherapy in patients with colorectal and anal cancers. The principal investigator will leverage their experience leading clinical trials at MD Anderson to analyze circulating tumor DNA (ctDNA) and extracellular RNA (exRNA)...
This $419,133 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of the "AsciTesPredictTM" platform - a novel "ex vivo tumor biosensor" technology using single-cell analysis to evaluate cancer cell identities and therapeutic sensitivities. The key product under this 3-year award is to harden the AsciTesPredictTM technology for wider deployment in research settings to...
This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a novel circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of immunotherapy in patients with non-small cell lung cancer. The $990,771 award, effective from September 2024 to August 2026, aims to build clinical data to support the utility of this epigenetic-based ctDNA assay, which can broadly detect...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai is for the development and optimization of a scalable, cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ) that jointly captures gene expression, chromatin accessibility, and DNA methylation. The goal is to apply this new technique to identify and target methylation-driven pathways in acute myeloid leukemia (AML). The...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $671,384.00 to The Medical University of South Carolina (MUSC) to develop new glycan biomarkers for the early detection and diagnosis of cholangiocarcinoma (CCA), a highly lethal form of liver cancer. The key products and services to be delivered under this 5-year grant include: Identifying changes in glycosylation patterns in CCA tissue and serum samples that can...
The National Cancer Institute (NCI) awarded a $646,186 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Nord Bio Inc. to develop and evaluate a non-invasive assay to detect and monitor tumor-derived cell-free DNA (cfDNA) levels in saliva for head and neck squamous cell carcinoma (HNSCC) patients. The project aims to compare the sensitivity of the saliva-based cfDNA assay to plasma/blood-based cfDNA testing, and to develop the experimental and computational methodology for...